Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Clavis Pharma Announces Results of the LEAP Study of CP-4126 in Metastatic Pancreatic Cancer

Published: Monday, November 19, 2012
Last Updated: Monday, November 19, 2012
Bookmark and Share
Clavis Pharma continues to focus on elacytarabine and its Phase III CLAVELA study in leukaemia patients.

Clavis Pharma ASA has announced the results of the LEAP (Low hENT1 and Adenocarcinoma of the Pancreas) study of CP-4126 (also known as CO-101), versus gemcitabine in metastatic pancreatic cancer.

The trial, which was conducted by partner Clovis Oncology, Inc., showed that there was no difference in overall survival between the two arms in either the primary analysis of the hENT1-low patient population, or in the overall intent-to-treat population.

Median survival in each arm was approximately six months with a hazard ratio of 0.99, and is consistent with the survival results from other gemcitabine studies in metastatic pancreatic cancer.

Adverse events were comparable between the two arms, and no differences were observed in any subgroup analyses.

Contrary to the results of numerous published retrospective studies, the study demonstrated that hENT1 status had no impact on survival for patients with metastatic pancreatic cancer treated with gemcitabine.

All development work with CP-4126 across all indications is now suspended by both Clavis Pharma and Clovis Oncology.

Clavis Pharma will continue to focus on elacytarabine and its CLAVELA Phase III study in patients with acute myeloid leukaemia (AML) who have failed prior therapy.

Recruitment into this study is expected to complete in Q4 2012 and top-line data are expected in Q1 2013.

Data from a Phase II study completed in 2009 and interim results from an elacytarabine/idarubicin combination study completed in 2012 highlight the promising efficacy and safety profile of elacytarabine in AML patients seen to date.

The final results of the combination study are due to be reported next month at the American Society of Haematology meeting in Atlanta, USA (8-11 December).

Olav Hellebø, Clavis Pharma CEO, said: “The results from the LEAP study are surprising and disappointing given the evidence we have seen from previous studies reported in the literature. This is bad news for patients who suffer from metastatic pancreatic cancer, which is a very difficult condition to treat. Meanwhile, we continue to believe in the potential of elacytarabine, our lead product, to become an effective new treatment option for acute myeloid leukaemia. We remain focused on completing the ongoing clinical trials in which elacytarabine is being investigated and in particular look forward to reporting the results from the pivotal Phase III CLAVELA study in the first quarter of 2013.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Clavis Pharma Provides Update on Pivotal LEAP Trial with CP-4126
64% of the 360 patients enrolled in the study are hENT1-low.
Monday, October 22, 2012
Clavis Pharma Announces Size of Initial hENT1-low Population in Pivotal LEAP Trial with CP-4126
65 percent of the initial 250 patients enrolled in the study are hENT1-low.
Monday, March 05, 2012
Clavis Pharma Announces the Completion of Study 002
Low hENT1 cut-off level determined for pivotal LEAP study of CP-4126 in patients with pancreatic cancer.
Friday, October 28, 2011
Clavis Pharma Second Quarter and First Half Report 2011
Clavis Pharma and Clovis Oncology expanded the LEAP study, evaluating CP-4126 vs. gemcitabine in pancreatic cancer patients.
Friday, August 26, 2011
Clavis Pharma Licenses LVT Compound CP-4033 to Translational Therapeutics for Development in Aggressive Thyroid Tumours
Clavis Pharma and Translational Therapeutics have entered into a strategic licensing agreement regarding the development and commercialization of CP-4033.
Monday, June 06, 2011
Scientific News
Potential of New Insect Control Traits in Agriculture
Researchers have discovered a protein that shows promise as an alternate corn rootworm control mechanism.
Fighting Cancer with Sticky Nanoparticles
Treatment that uses bioadhesive nanoparticles drug carriers proved more effective than conventional treatments for certain cancers.
Fighting Plant Pathogens with RNA
Researchers develop strategy that could lead to environmentally friendly fungicide to fight pathogens.
Smart Material Hunts Cancers
Team has created smart material that locates and images cancer or tumour sites in tissue.
Examining mtDNA May Help Identify Unknown Ancestry That Influences Breast Cancer Risk
Researchers studying mtDNA in a group of triple negative breast cancer patients found that 13 percent of participants were unaware of ancestry that could influence their risk of cancer.
Gene Therapy Technique May Help Prevent Cancer Metastasis
Gene-regulating RNA molecules could help treat early-stage breast cancer tumors before they spread.
Enhancing Antibiotics to Defeat Resistant Bacteria
Scientists enhance ability of antibiotics to defeat resistant types of bacteria using molecules called PPMOs
MRI Guidance Aids Stem Cell Delivery
Scientists have delivered stem cells to the brain with unprecedented precision, infusing the cells under real-time MRI guidance.
High-Capacity Nanoparticles
New type of nanoparticle can now have three or more drugs packaged within it, allowing for customised cancer therapy.
UTSW Creates Nanoparticles That Target Lung Cancer Cells
Researchers at UTSW have developed a synthetic polymers that could deliver nucleic acid drugs while possessing enough structural diversity to discover cancer cell-specific nanoparticles.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!